company background image
NKTR

Nektar Therapeutics NasdaqGS:NKTR Stock Report

Last Price

US$3.09

Market Cap

US$580.8m

7D

18.4%

1Y

-70.5%

Updated

04 Feb, 2023

Data

Company Financials +

NKTR Stock Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.

NKTR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Nektar Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nektar Therapeutics
Historical stock prices
Current Share PriceUS$3.09
52 Week HighUS$11.59
52 Week LowUS$1.99
Beta0.92
1 Month Change29.29%
3 Month Change-18.04%
1 Year Change-70.46%
3 Year Change-86.33%
5 Year Change-95.86%
Change since IPO-17.60%

Recent News & Updates

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Recent updates

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Mar 09
Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Nektar Therapeutics: Beaten Down By 2020

Jan 26

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Jan 13
We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

Dec 09
Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Oct 05
Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks

Sep 29

Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration

Sep 23

Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party

Aug 27

Nektar In Renal Cell Carcinoma: An Overview

Jul 10

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Jul 06
We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Nektar Therapeutics shares rise on narrower Q1 loss

May 07

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Apr 05
We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Slashed This Year's Estimates

Feb 28
Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Slashed This Year's Estimates

Have Nektar Therapeutics (NASDAQ:NKTR) Insiders Been Selling Their Stock?

Feb 19
Have Nektar Therapeutics (NASDAQ:NKTR) Insiders Been Selling Their Stock?

Would Shareholders Who Purchased Nektar Therapeutics' (NASDAQ:NKTR) Stock Three Years Be Happy With The Share price Today?

Jan 25
Would Shareholders Who Purchased Nektar Therapeutics' (NASDAQ:NKTR) Stock Three Years Be Happy With The Share price Today?

Nektar to sell Adynovate, Movantik Royalties for $150M

Dec 22

Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Dec 21
Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Nektar Therapeutics raised to ‘Hold’ from ‘Sell’ at CFRA on encouraging clinical data

Dec 16

Dosing underway in Nektar Therapeutics' study of NKTR-255+cetuximab in head, neck and colorectal cancer

Dec 15

Shareholder Returns

NKTRUS PharmaceuticalsUS Market
7D18.4%-0.5%1.7%
1Y-70.5%4.6%-9.6%

Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: NKTR underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is NKTR's price volatile compared to industry and market?
NKTR volatility
NKTR Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NKTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: NKTR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990740Howard Robinhttps://www.nektar.com

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates.

Nektar Therapeutics Fundamentals Summary

How do Nektar Therapeutics's earnings and revenue compare to its market cap?
NKTR fundamental statistics
Market CapUS$580.78m
Earnings (TTM)-US$454.15m
Revenue (TTM)US$95.04m

6.1x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NKTR income statement (TTM)
RevenueUS$95.04m
Cost of RevenueUS$21.57m
Gross ProfitUS$73.48m
Other ExpensesUS$527.63m
Earnings-US$454.15m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.42
Gross Margin77.31%
Net Profit Margin-477.85%
Debt/Equity Ratio0%

How did NKTR perform over the long term?

See historical performance and comparison